Prioritisation of Adverse Drug Events Leading to Hospital Admission and Occurring during Hospitalisation: A RAND Survey.

RAND survey adverse drug events consensus drug-related side effects medication safety prioritisation

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
22 Jul 2022
Historique:
received: 30 04 2022
revised: 05 07 2022
accepted: 11 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

(1) Adverse drug events (ADEs) are a common cause of emergency department visits and occur frequently during hospitalisation. Instruments that facilitate the detection of the most relevant ADEs could lead to a more targeted and efficient use of limited resources in research and practice. (2) We conducted two consensus processes based on the RAND/UCLA appropriateness method, in order to prioritise ADEs leading to hospital admission (panel 1) and occurring during hospital stay (panel 2) for inclusion in future ADE measurement instruments. In each panel, the experts were asked to assess the "overall importance" of each ADE on a four-point Likert scale (1 = not important to 4 = very important). ADEs with a median rating of ≥3 without disagreement were defined as "prioritised". (3) The 13 experts in panel 1 prioritised 38 out of 65 ADEs, while the 12 experts in panel 2 prioritised 34 out of 63 ADEs. The highest rated events were acute kidney injury and hypoglycaemia (both panels), as well as Stevens-Johnson syndrome in panel 1 and rhabdomyolysis in panel 2. (4) The survey led to a set of ADEs for which there was consensus that they were of particular importance as presentations of acute medication-related harm, thereby providing a focus for further medication safety research and clinical practice.

Identifiants

pubmed: 35893345
pii: jcm11154254
doi: 10.3390/jcm11154254
pmc: PMC9332872
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Federal Ministry of Education and Research
ID : 01ZZ1910*

Références

Int J Qual Health Care. 2012 Jun;24(3):239-49
pubmed: 22495574
Value Health. 2012 Sep-Oct;15(6):868-75
pubmed: 22999137
Curr Pharm Des. 2007;13(1):119-26
pubmed: 17266591
Nat Rev Drug Discov. 2009 Oct;8(10):779-82
pubmed: 19763106
J Am Geriatr Soc. 2018 Nov;66(11):2079-2085
pubmed: 30335185
Aust Health Rev. 2014 Feb;38(1):51-7
pubmed: 24351707
J Am Geriatr Soc. 2019 Apr;67(4):674-694
pubmed: 30693946
J Patient Saf. 2021 Dec 1;17(8):e1040-e1049
pubmed: 32175969
Pharmacoepidemiol Drug Saf. 2015 Feb;24(2):176-86
pubmed: 24934134
Saudi Pharm J. 2016 Jul;24(4):485-93
pubmed: 27330379
Pharmacoepidemiol Drug Saf. 2021 May;30(5):636-643
pubmed: 33630347
SAGE Open Med. 2021 Aug 18;9:20503121211039099
pubmed: 34422271
Expert Opin Drug Metab Toxicol. 2012 May;8(5):527-30
pubmed: 22512705
BMC Pharmacol Toxicol. 2020 Mar 23;21(1):25
pubmed: 32293547
Cochrane Database Syst Rev. 2018 Sep 03;9:CD008165
pubmed: 30175841
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Dtsch Arztebl Int. 2018 Apr 13;115(15):251-258
pubmed: 29735005
Cochrane Database Syst Rev. 2016 Feb 20;2:CD008986
pubmed: 26895968
Eur J Clin Pharmacol. 2013 Dec;69(12):1985-96
pubmed: 23955174
Dtsch Arztebl Int. 2010 Aug;107(31-32):543-51
pubmed: 20827352
Eur J Clin Pharmacol. 2022 Feb;78(2):267-278
pubmed: 34661726
PLoS One. 2018 Oct 11;13(10):e0205426
pubmed: 30308067
Eur J Clin Pharmacol. 2022 Feb;78(2):159-170
pubmed: 34611721
Eur J Clin Pharmacol. 2017 Dec;73(12):1539-1549
pubmed: 28871436
Drugs Real World Outcomes. 2015;2(4):387-395
pubmed: 26689834
Arch Intern Med. 2009 May 11;169(9):894-900
pubmed: 19433702
N Engl J Med. 2016 Mar 17;374(11):1053-64
pubmed: 26981935
Arch Intern Med. 1997 Jul 28;157(14):1531-6
pubmed: 9236554
Am J Health Syst Pharm. 2017 Nov 1;74(21):1774-1783
pubmed: 29070499

Auteurs

Annette Haerdtlein (A)

Institute of General Practice and Family Medicine, University Hospital, LMU Munich, 80336 Munich, Germany.
Doctoral Program Clinical Pharmacy, University Hospital, LMU Munich, 81377 Munich, Germany.

Anna Maria Boehmer (AM)

Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany.

Katharina Karsten Dafonte (K)

Institute of Clinical Chemistry and Clinical Pharmacology, University of Bonn, 53127 Bonn, Germany.

Marietta Rottenkolber (M)

Institute of General Practice and Family Medicine, University Hospital, LMU Munich, 80336 Munich, Germany.

Ulrich Jaehde (U)

Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany.

Tobias Dreischulte (T)

Institute of General Practice and Family Medicine, University Hospital, LMU Munich, 80336 Munich, Germany.

Classifications MeSH